Table 2 Main antimicrobial used in the 66 included patients with native methicillin-susceptible Staphylococcus aureus native bone and joint infection
All patients (n = 66) | Treatment failure (n = 16) | Favorable outcome (n = 50) | p | ||
|---|---|---|---|---|---|
i.v anti-staphylococcal penicillin | 49 (74.2%) | 11 (68.8%) | 38 (76.0%) | 0.743 | |
Dose (mg/kg/day) | 144.6 (133.3-169.0) | 141.2 (133.3-150.0) | 144.9 (133.6-172.7) | 0.606 | |
Duration (weeks) | 6.0 (3.0-8.0) | 6.7 (4.1-12.2) | 5.2 (2.7-7.4) | 0.250 | |
Glycopeptides | 25 (37.9%) | 7 (43.8%) | 18 (36.0%) | 0.768 | |
Vancomycine, | 10 (15.2%) | 1 (6.3%) | 9 (18.0%) | 0.430 | |
Dose (mg/kg/day) | 26.0 (20.3-30.5) | 25 | 27.0 (19.2-31.3) | NC | |
Teicoplanin | 22 (33.3%) | 6 (37.5%) | 16 (32.0%) | 0.764 | |
Dose (mg/kg/day) | 5.7 (4.1-7.0) | 7.2 (5.4-8.4) | 5.2 (3.9-6.5) | 0.197 | |
Duration | 3.4 (2.6-7.6) | 3.4 (1.9-16.1) | 3.9 (2.8-6.7) | 0.832 | |
Aminoglycosides | 38 (57.6%) | 9 (56.3%) | 29 (58.0%) | 1.000 | |
Rifampin | 36 (54.5%) | 9 (56.3%) | 27 (54.0%) | 1.000 | |
Dose (mg/kg/day) | 18.8 (14.6-21.2) | 18.0 (14.6-21.4) | 18.8 (15.2-20.8) | 0.841 | |
Duration (weeks) | 20.3 (2.7-34.6) | 27.5 (11.8-53.1) | 16.0 (2.7-25.3) | 0.334 | |
Fluoroquinolones | 62 (93.9%) | 15 (93.8%) | 47 (94.0%) | 1.000 | |
Ofloxacin dose (mg/kg/day) | 6.7 (5.8-7.5) | 7.1 (6.3-7.5) | 6.35 (5.7-7.3) | 0.240 | |
Duration (weeks) | 14.6 (8.0-27.6) | 17.0 (10.9-31.9) | 14.6 (7.6-24.4) | 0.397 | |
Macrolid group | 46 (69.7%) | 10 (62.5%) | 36 (72.0%) | 0.538 | |
Clindamycin | 17 (25.8%) | 6 (37.5%) | 11 (22.0%) | 0.324 | |
Pristinamycin | 33 (50.0%) | 5 (31.3%) | 28 (56.0%) | 0.150 | |
Linezolid | 6 (9.1%) | 1 (6.3%) | 5 (10.0%) | 1.000 | |
Fucidic acid | 4 (6.1%) | 1 (6.3%) | 3 (6.0%) | 1.000 | |
Fosfomycin | 13 (19.7%) | 4 (25.0%) | 9 (18.0%) | 0.719 | |
Cotrimoxazole | 2 (3.0%) | 1 (6.3%) | 1 (2.0%) | 0.429 | |